<DOC>
	<DOCNO>NCT00771004</DOCNO>
	<brief_summary>The purpose study determine effect pioglitazone , daily ( QD ) , heart functioning , stent implantation .</brief_summary>
	<brief_title>Efficacy Pioglitazone Myocardial Function Patients Undergoing Coronary Stent Implantation .</brief_title>
	<detailed_description>Type 2 diabetes increase risk coronary heart disease least two three fold compare non-diabetic subject . Moreover , prospective study show significant correlation several glycemic confounders morbidity coronary heart disease even patient without diabetes mellitus . In patient previously diagnose coronary heart disease , impair glucose tolerance find 30 67 % . The cardiovascular risk patient insulin resistance , without glucose intolerance become apparent within recent year quantitative coronary angiographic study reveal correlation severity coronary heart disease impair glucose tolerance . A new pharmaceutical class intervention insulin resistance , peroxisome proliferator activate receptor ( gamma ) agonists successfully introduce treatment type 2 diabetes . Beyond metabolic effect glucose lipid metabolism , peroxisome proliferator activate receptor ( gamma ) agonists show exert couple pleiotropic , anti-inflammatory vasoprotective effect patient type 2 diabetes impair glucose tolerance . The incidence severity peri-procedural myocardial injury percutaneous coronary intervention stent implantation diabetic non-diabetic patient important prognostic confounder patient . Different laboratory biomarkers investigate diagnostic tool estimation risk peri-procedural myocardial injury . Recent study convincingly demonstrate risk subsequent ischemic heart event related extent cardiac troponin CK-MB increase coronary intervention , prognosis individual usually bad patient develop increase biomarkers . In recent trial show pretreatment atorvastatin could reduce procedural myocardial injury elective coronary intervention . The incidence Troponin I increase 48 % placebo group compare 20 % atorvastatin group . The aim study investigate effect pioglitazone incidence peri-procedural myocardial injury patient undergo percutaneous coronary intervention stent implantation . Total participation time anticipate 3 week .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Stable coronary artery disease plan percutaneous coronary intervention stent implantation . Type IIdiabetics and/or IRIS II score great equal 50 ( measure identification patient insulin resistance increase vascular risk ) . Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . A planned percutaneous coronary intervention stent implantation le 15 day screen visit . Planned multivessel intervention . Use systemic corticosteroid within last 3 month prior screen visit . Anamnestic history hypersensitivity study drug drug similar chemical structure . History severe multiple allergy . Treatment investigational drug within 3 month trial entry earlier participation present study . Have one unexplained episode severe hypoglycemia ( define require assistance another person due disable hypoglycemia ) within 6 month prior screen visit . Progressive fatal disease . History drug alcohol abuse within last 10 year . A history significant cardiovascular ( New York Health Association stage II IV ) , respiratory , gastrointestinal , hepatic ( alanine aminotransferase great 2.5 time normal reference range ) , renal ( creatinine great 1.2 mg/dL woman great 1.5 men and/or glomerular filtration rate le 45 ) , neurological , psychiatric and/or hematological disease judge Investigator . Pretreatment peroxisome proliferatoractivated receptor ( gamma ) agonists within 3 month prior screen . If insulin therapy applicable : initiation insulin therapy within last 3 month . If statin therapy applicable : change medication within last 4 week . Myocardial infarction within 3 month prior screen visit . Blood donation within last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>drug effect</keyword>
	<keyword>Type II Diabetes</keyword>
	<keyword>Angioplasty , Transluminal , Percutaneous Coronary</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Heart</keyword>
	<keyword>physiology</keyword>
	<keyword>function</keyword>
</DOC>